



Newsletter Actionnaires
Decembre 2022

Our reflections on 2022 and what 2023 holds

Dear valued shareholder,

The past six months have been transformative for Genomic Vision. Following the appointment of new members to the supervisory and executive board, the Company has strengthened its leadership team while refining its strategy and forging new international partnerships with global partners.

This year, we appointed Emilie Chataignier, an expert in finance and investment banking and Lionel Seltz, a highly experienced executive, to the Executive Board of the Company. Lionel has also taken the position of Chief Financial Officer. This year has also seen my return as Chief Executive Officer of Genomic Vision and I look forward to leading our company as we embark on the next stage of growth.

We are in the midst of a biopharmaceutical revolution, developing increasingly sophisticated and targeted advanced therapies – and doing so in ways that are faster, better and more cost-effective. Highly accurate, fast and accessible genomic analysis is the foundation for this trend, enabling the development of ever-better cell and gene therapies and supporting the industrialization of bioproduction with the required levels of quality control throughout the process.

Under strong leadership, and with the guidance of our experienced Board members, I believe Genomic Vision is well-positioned to capitalize on the rapidly growing demand for highly accurate, fast and accessible solutions for genome characterization.

Partnerships

Over the course of 2022, we further strengthened our balance sheet by securing up to €30 million of funding with our long-standing finance partner, Winance. We have made progress in making our products and services available to partners across the world. Most recently, we [announced](#) a collaboration with the Centre National de la Recherche Scientifique (CNRS), the French state research organization, to launch a four-year core scientific program with the Cancer Research Center of Marseille (CRCM) for the development of companion diagnostic tests using Genomic Vision's TeloSizer® product. Earlier in the year, we announced that our technology is now used by the Department of Cell Biology, Microbiology & Molecular Biology at the University of South Florida to better understand the mechanisms that maintain the stability of the human genome.

Innovation and the continued development of our technology and product is at the heart of our strategy. We have [selected](#) a world-leading technology consultancy, Cambridge Consultants, to jointly develop the next generation of our image readout platform for the analysis of structural and functional genome modifications. This new cost-effective image readout platform pioneered by

Genomic will help achieve significantly higher throughput, reduced hands-on time and improved user experience, while reducing costs.

In the coming year, we will be working to expand our network of partners, collaborators and clients to bring about a new era of genomic analysis and to facilitate the industrialization of cell and gene therapies. Genomic Vision is determined to capitalize on this important trend and we are now in a stronger-than-ever position to achieve continued success.

Thank you very much for your trust and support. I would like to wish you a very happy holiday and a great start to the New Year!

Aaron Bensimon

CEO of Genomic Vision